Skyrizi from AbbVie Inc. - psoriasis control with quarterly dosing

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 05:53. Details in the imprint.

Skyrizi from AbbVie Inc. sits in a patient’s fridge, a slim prefilled pen with a click that is more muted than many insulin pens and a needle that disappears as soon as the dose is in. For many psoriasis patients that quiet click marks the start of a different relationship with their skin. The plastic feels smooth and cool in the hand, more medical tool than gadget.

How Skyrizi works

Skyrizi is a biologic therapy that targets interleukin-23, a key cytokine involved in the inflammatory cascade that drives plaque psoriasis. After two starter doses in the first month, the treatment typically moves to a single subcutaneous injection every twelve weeks, which sharply reduces the number of treatment days per year compared with older regimens. For a patient juggling work and family, that quarterly rhythm can feel more manageable than frequent clinic visits.

In pivotal Phase 3 studies, a large proportion of patients achieved PASI 90 or even PASI 100 responses, meaning nearly or completely clear skin after several months of therapy. Those numbers are not just dry endpoints; for someone who used to leave white scales on a dark office chair, the difference shows up every morning in the mirror. Dermatologist Dr. Kenneth Gordon has described IL-23 inhibitors like Skyrizi as setting a new bar for psoriasis control in routine practice.

The dosing experience

Skyrizi is supplied as a prefilled syringe or on-body injector, designed for self-administration after training by a nurse or dermatologist. Patients are taught to rotate injection sites on thighs, abdomen or upper arms, to wait for the pen’s quiet click, and to watch a small indicator window that confirms the dose has gone in. The injection fluid itself is clear and slightly viscous; some patients report a brief sting, followed by a mild sense of relief once they know the three-month countdown has started.

The maintenance schedule, with a single injection every three months after the initial phase, reduces the logistical burden of chronic treatment. For employers, that can mean fewer half-days taken for appointments, and for families, it may mean one less recurring calendar alarm. Still, the need for cold-chain storage and proper handling remains, so the pen is more at home next to yogurt and juice in the fridge than in a travel wash bag.

Benefits and limits

One practical appeal of Skyrizi is that most of the administration work shifts from the clinic to the living room. A dermatology nurse like Sarah Martinez will typically walk new patients through their first injection, guiding their hand as they press the device to the skin and wait for the click. After that, many patients feel confident enough to take over themselves, which can strengthen a sense of control over the disease.

However, biologic therapy is not a casual choice. The drug is prescribed for moderate to severe plaque psoriasis and also approved for conditions such as psoriatic arthritis and Crohn’s disease, with each indication carrying its own dosing nuances and safety profile. Patients need screening for infections and discussion of risks like upper respiratory tract infections or injection-site reactions. For those who prefer to avoid systemic immunomodulation, topical therapies remain the first line, even if their efficacy is more modest.

Pricing and access

Skyrizi is a high-cost specialty medicine, typically reimbursed through public or private insurance plans subject to prior authorization. For a patient in the US, the list price can run into several thousand dollars per dose, although negotiated rebates and patient-assistance programs may reduce out-of-pocket costs. In Europe and other markets, national health systems often negotiate different price points and set treatment criteria, which can limit access for mild disease.

In Germany, Skyrizi is usually handled through dermatology clinics and hospital pharmacies rather than over-the-counter channels, so consumers will not find it on a regular online pharmacy shelf. For investors, the revenue potential is tied less to individual pen sales than to long-term treatment persistence and expansion into new inflammatory indications. Health-technology assessments and guideline updates can influence both.

AbbVie and the stock

Skyrizi is one of the immunology products that AbbVie highlights as part of its pipeline designed to offset erosion in older franchises. The company reports continuing investment in IL-23 research and in real-world evidence to support long-term use in chronic conditions. Bottom line, AbbVie shares (ISIN US00287Y1091) trade on the New York Stock Exchange in US dollars and reflect expectations that products like Skyrizi will deliver durable cash flows.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.